Antiviral Therapies

SAN FRANCISCO — Ensitrelvir reduced transmission of SARS-CoV-2 by 67% when given to uninfected household contacts of a person with COVID-19 within 3 days of that person developing symptoms, researchers reported.

Influenza poses significant health and socioeconomic threats despite cases drastically dropping during the COVID-19 pandemic.

The current understanding of long COVID’s pathogenesis may be better served by looking to other diseases and syndromes, particularly fibromyalgia, according to a speaker at the 2023 Biologic Therapies Summit.

As the COVID-19 pandemic has moved from beta to delta to omicron, often with remarkable speed and unpredictable epidemiology, the efficacy of therapeutic approaches has risen and fallen accordingly.

When treated with direct-acting antiviral therapy, patients with chronic hepatitis C virus infection were at a lower risk for end-stage kidney disease and the composite of ESKD or death, according to a speaker at ASN Kidney week.

Core protein allosteric modulator RO7049389 was safe and demonstrated antiviral activity in patients with chronic hepatitis B infection, according to research published in Lancet Gastroenterology and Hepatology.